Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Investing.com - Jefferies raised its price target on Masimo Corp . (NASDAQ:MASI) to $170.00 from $158.00 on Wednesday, while maintaining a Hold rating on the stock. The new target represents a modest premium to the current trading price of $163.88, with the stock already up over 48% in the past year.
The price target increase follows Masimo’s second-quarter results, which showed sales of $370 million, representing a 7% year-over-year increase on a constant currency basis, slightly above consensus estimates of $369 million. According to InvestingPro data, the company maintains a strong financial health score of GOOD, with liquid assets exceeding short-term obligations.
Masimo reported earnings per share of $1.33, marking a 46% increase compared to consensus expectations of $1.22, according to Jefferies.
The medical technology company maintained its fiscal year 2025 constant currency sales growth guidance of 8-11%, with a $5 million increase to reported sales guidance. Masimo raised its EPS guidance range to $5.20-$5.45 from the previous $4.80-$5.15, as tariff impacts are expected to be approximately 50% lower than previously anticipated.
Jefferies noted that while "true incremental" contracts declined year-over-year, Masimo attributed this to order timing and cited a strong pipeline of potential business.
In other recent news, Masimo Corporation reported its second-quarter 2025 earnings, exceeding expectations with an earnings per share (EPS) of $1.33, above the anticipated $1.22. The company’s revenue reached $371 million, slightly surpassing the forecast of $368.64 million. These results reflect a positive performance for the quarter. The company’s stock responded positively to the earnings announcement. Analyst firms have taken note of Masimo’s performance, though specific upgrades or downgrades were not mentioned in the reports. These developments highlight the company’s financial health and its ability to outperform market predictions. Investors may find these results encouraging as they consider their positions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.